遗传性出血性毛细血管扩张症鼻出血的药物治疗:一项Meta分析
该系统评价与Meta分析纳入8项随机对照试验,评估遗传性出血性毛细血管扩张症(HHT)鼻出血的药物治疗。他莫昔芬在鼻出血频率和严重程度上优于安慰剂,黏膜下贝伐珠单抗可缩短鼻出血持续时间;药物治疗对平均血红蛋白浓度和生活质量无显著影响。
要点
- 他莫昔芬可改善HHT鼻出血的频率和严重程度。
- 黏膜下贝伐珠单抗可缩短鼻出血持续时间。
- 药物治疗未显著改变平均血红蛋白浓度和生活质量。
核心结论
- 仅有有限证据表明他莫昔芬改善HHT鼻出血频率、黏膜下贝伐珠单抗缩短鼻出血持续时间。
- 药物治疗未显著影响HHT患者的平均血红蛋白浓度和生活质量。
研究设计与样本
- 纳入比较药物治疗与安慰剂治疗HHT鼻出血的随机临床试验,共识别8项研究。
- 采用随机效应模型合成总体效应,以I2统计量评估异质性。
主要发现
- 贝伐珠单抗、氨甲环酸和雌激素无论给药途径均对鼻出血发作频率无显著影响。
- 他莫昔芬在鼻出血频率和严重程度上均优于安慰剂。
- 鼻喷贝伐珠单抗、口服或鼻喷氨甲环酸及鼻喷雌激素对鼻出血持续时间与安慰剂无显著差异。
- 黏膜下贝伐珠单抗组鼻出血持续时间较低(均数差:-219.00 min/月,95% CI:-271.90至-166.10)。
- 药物治疗对平均血红蛋白浓度(合并均数差:-0.23 mg/dL,95% CI:-0.65至0.20,I2=0%)和生活质量(合并标准化均数差:0.07,95% CI:-0.16至0.30,I2=0%)无显著改变。
临床怎么用
- 对于HHT鼻出血患者,他莫昔芬可能减少发作频率并减轻严重程度,黏膜下贝伐珠单抗可能缩短出血持续时间。
- 贝伐珠单抗、氨甲环酸和雌激素的其他给药途径未显示对鼻出血频率或持续时间的显著获益。
- 药物治疗决策需结合有限证据,并注意其未改善血红蛋白浓度和生活质量。
局限性
- 仅识别8项研究,证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this study (PROSPERO ID: CRD42017081952) was to evaluate medical treatment for epistaxis from hereditary hemorrhagic telangiectasia (HHT). DATA SOURCES: PubMed, Embase, Scopus, and Cochrane Library databases were interrogated from their inceptions to November 2017. REVIEW METHODS: Randomized clinical trials comparing medical treatment with placebo for epistaxis of HHT were included. We used a random-effects model to synthesize overall effects. Heterogeneity was evaluated with the I2 statistic. RESULTS: Eight studies were identified after systematic searching. The use of bevacizumab (BV), tranexamic acid, and estrogen, regardless of the route of administration, had no significant influence on frequency of episodes. Tamoxifen was superior to placebo in both frequency and severity of epistaxis. For duration of epistaxis, nasal spray BV, oral or nasal spray tranexamic acid, and nasal spray estrogen had no significant differences versus placebo, but patients receiving submucosal BV showed lower duration of epistaxis (mean difference: -219.00 min/mo, 95% CI: -271.90 to -166.10). Medical treatment for HHT had no significant changes of mean hemoglobin concentration (pooled mean difference: -0.23 mg/dL, 95% CI: -0.65 to 0.20, I2 = 0%) or quality of life (pooled standardized mean difference: 0.07, 95% CI: -0.16 to 0.30, I2 = 0%). CONCLUSIONS: Only limited evidence provides a benefit on frequency of epistaxis by treatment with tamoxifen and duration of epistaxis by treatment with submucosal BV among patients with HHT. Mean hemoglobin concentration and quality of life were not influenced by medical treatment.
引用
- Hsu YP, Hsu CW, Bai CH, et al. Medical Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Meta-analysis. Otolaryngol Head Neck Surg. 2018. PMID: 30200816. doi:10.1177/0194599818797316
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。